TCM
TGTX icon

Tygh Capital Management’s TG Therapeutics TGTX Stock Holding History

Tygh Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1.48M Sell
78,113
-155
-0.2% -$4.02K 0.19% 81
2021
Q3 		$2.6M Buy
+78,268
New +$2.42M 0.35% 82

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Tygh Capital Management's TGTX Position: Q4 2021 in Review

Tygh Capital Management reduced its TG Therapeutics (TGTX) stake by 0.2% in Q4 2021, selling an estimated $4.02K and leaving 78,113 shares worth $1.48M. The position accounts for 0.19% of the portfolio, ranked #81.

Tygh Capital Management first reported a position in TGTX in Q3 2021 and has held it in 2 quarters since. The position peaked at $2.6M in Q3 2021. 194 funds tracked by Wall St. Rank hold TGTX as of Q4 2021.

  • Tygh Capital Management held 78,113 shares of TG Therapeutics worth $1.48M as of Q4 2021.
  • Tygh Capital Management sold 155 TG Therapeutics shares in Q4 2021, an estimated $4.02K.
  • TG Therapeutics made up 0.19% of Tygh Capital Management's portfolio in Q4 2021, its #81 holding.
  • Tygh Capital Management first reported a position in TG Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • Tygh Capital Management's TG Therapeutics position peaked at $2.6M in Q3 2021.
  • 194 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2021.

Based on Tygh Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.